NCT07628829 Neonatal Neurological Observation With Video AI
| NCT ID | NCT07628829 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Artemis AI Labs |
| Condition | Neonatal Encephalopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-07-13 |
| Primary Completion | 2027-07-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-07-13 with a primary completion date of 2027-07-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
NeoNOVA is a multi-site, prospective, single-arm, silent observational study to determine: among (Population) infants admitted to newborn services during their inpatient hospital stay, whether (Intervention) continuous bedside non-contact high definition video running real-time AI analysis of anatomic landmarks and movement, (Comparison) compared against human-labeled video frames and standardized clinical exams, will (Outcome) accurately localize infant anatomic landmarks (primary objective; outcome median position error in pixels) and demonstrate a statistically significant association between a video-derived movement index and clinical measures of patient neurological exams (secondary objective; outcomes N-PASS and modified Sarnat exams).
Eligibility Criteria
Inclusion Criteria: * Signed and dated informed consent from at least one parent or legally authorized representative (LAR) who is at least 18 years old. * Parent/LAR expresses willingness to comply with study procedures for the duration of the infant's hospital stay. * Infant of any sex (including intersex/undetermined) admitted to newborn services (including the NICU) at a participating hospital. Exclusion Criteria: * Parents or LAR unable to provide informed consent or are under the age of 18. * Non-viable neonates
Contact & Investigator
Benjamin Glicksberg, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT07628829 clinical trial?
This trial is open to participants of all sexes, studying Neonatal Encephalopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07628829 currently recruiting?
Yes, NCT07628829 is actively recruiting participants. Contact the research team at saum@artemisailabs.com for enrollment information.
Where is the NCT07628829 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT07628829 clinical trial?
NCT07628829 is sponsored by Artemis AI Labs. The principal investigator is Benjamin Glicksberg, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 200 participants.